Mechanistic Basis for 5-HT2AR Over 5-HT2BR Activation (2026)

https://doi.org/10.1038/s41467-026-77659-x

Selective 5-HT2AR agonism without 5-HT2BR activation is critical for safe psychedelic-inspired therapeutics. Here, we systematically probe the ligand-binding pockets of 5-HT2AR and 5-HT2BR and identify steric and conformational constraints at the side-extended pocket (SEP) and extended binding pocket (EBP) that dictate ligand orientation and receptor signaling. Guided by these insights, we design derivatives across tryptamine and phenethylamine scaffolds that integrate SEP and EBP engagement with scaffold modification to reinforce 5-HT2AR activation while limiting 5-HT2BR activity. Cryo-EM structures of 5-HT2AR and 5-HT2BR bound to IHCH-2330, a selective 5-HT2AR agonist and 5-HT2BR antagonist, confirm the design principle. These findings show differential activation mechanisms between 5-HT2AR and 5-HT2BR and provide a rational framework for engineering safer, functionally selective serotonergic compounds, mitigating 5-HT2BR–mediated side effects while preserving therapeutic efficacy.

12 Upvotes

83% Upvoted

u/adams4096 1d ago

Interesting exploit! Why not over 5ht2c also? A dual 5ht2a - 5ht2b biased agonist ( 5ht2c functional antagonist) for that pathway should be very therepautic acutely tough

2

u/Kalki_X 1d ago

Arguably even 5-HT2B has relevant psychoactive effects, but it's important not to compartmentalise things too much (5-HT1A agonism is highly therapeutic alongside 5-HT2A agonism).

The FDA advised that newly designed psychedelics should avoid 5-HT2B agonism.

2

u/adams4096 1d ago edited 1d ago

Yes, for the possible induction of valvulopathy with chronic dosing. As i think they are developing psychedelics as psychoplastogen as the main focus. You can develop both, tough, it would be interesting. One used in acute dosing the other in chronic dosing( maybe? It wouldnt escape tolerance anyway, right? For the "selective" 5ht2a agonist (as it wasnt tested for other receptors, it seems?!?) It will mantain the effect but more subtle over the long term? What is their target?

2

u/Kalki_X 1d ago

Ah yes by 'relevant psychoactive effects' I was ignoring the non-hallucinogenic notion.

The full receptor profile is in the supplementary material. There were about 7 IHCH compounds made including tryptamines, IHCH-2330 was the only one that blocked 5-HT2B.

1

u/adams4096 1d ago

Cool, thank you! It seems a pretty potent full agonist, for the Gq pathway at least. (5ht2c).

"Ah yes by 'relevant psychoactive effects' I was ignoring the non-hallucinogenic notion. "

Do you mean psychoplastogen devoid of pro-hallucinatory effects? Because 5ht2b it isnt involved in hallucinogenesis, if i remember correctly

1

u/Kalki_X 1d ago edited 1d ago

I'm interpreting all of LSDs polypharmacology as relevant and contributing to the drugs psychoactivity. 5-HT2A may indeed be a key player but the other receptors seem to assist in the "quality" of the psychoactivity eg HT5–7, the dopaminergic and α2-adrenergic effects.

1

u/adams4096 1d ago

Yes sure, that whats give each compound its richness and uniqueness, just a methyl group and BUM right different in vivo effect, biologically speaking.

u/AutoModerator 2d ago

Dear commenters,

You may be able to use Sci-Hub, LibGen or /r/scholar to remove barriers to your learning by allowing you to access this research. There is also the Sci-Hub Now extension for your browser.

You can use the "report" feature to remove this comment - just mark it as spam.

I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.